
    
      Study Description: This is a retrospective review that includes all patients with NF1
      enrolled on natural history and treatment trials at the National Cancer Institute (NCI) from
      1/1/1998 to 1/1/2020, excluding patients referred for treatment of MPNST.

      Objective: To describe the clinical and demographic characteristics of NF1 study participants
      who come for evaluation at the NCI and to compare the risk of MPNST formation in patients
      treated with MEK 1/2 inhibitor (MEKi) or other PN-directed treatment.

      Study Population: All participants with NF1 seen at the NIH from 1/1/1998 to 1/1/2020

      Description of Sites/Facilities conducting research: This is a single site study initiated by
      the Pediatric Oncology Branch at the National Cancer Institute

      Study Duration: Data abstraction to completion of data analyses will take 3-6 months.
    
  